89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.
Why We're Green
Here are just some of the ways we have and will continue to work towards being a sustainable business:
-Utilizing non-toxic cleaning products
-Sourcing energy efficient appliances and electronics
-Installing low flow water fixtures
-Purchasing recycled content paper products
-Utilizing/ purchasing reusable products